Highlights of the ESMO 2017 lung cancer program | Lecia Sequist Published 2019-03-25 Download video MP4 360p Recommendations 21:08 Pathologic testing for ALK and ROS1 aberrations in NSCLC | Frédérique Penault-Llorca 37:34 Managing ROS1 fusion-positive NSCLC in Europe and the USA | Panel discussion 30:02 PD-L1 expression in early NSCLC: Interpreting the data so far | Heather Wakelee & Nasser Altorki 19:18 ALK fusion-positive NSCLC: International approaches to management | Panel discussion 17:29 The role of surgery in early-stage NSCLC management | Jessica Donington 03:07 EV-301 update reinforces third-line enfortumab vedotin benefit in advanced UC | Jonathan Rosenberg 05:11 Genitourinary cancer highlights from the 2022 ASCO Annual Meeting | Tian Zhang 18:46 Approach to the Exam for Parkinson's Disease 1:56:10 Sunlight: Optimize Health and Immunity (Light Therapy and Melatonin) 03:42 Exploratory data suggest potential of epigenetic biomarkers in advanced UC | Joaquim Bellmunt 44:39 Leaving Home At Eight | Boarding School Children 05:14 IMvigor130 analysis stresses need to standardize PD-L1 expression assessment | Enrique Grande Pulido 02:53 COSMIC-313 points to first-line triplet option for advanced RCC | Toni Choueiri 41:06 What is Cervical Stenosis? | Jeffrey Cantor, MD 13:50 4 Tricks for when doctors gaslight you - Dr. Kaveh LIVE 04:20 Neoadjuvant avelumab plus axitinib active in high-risk RCC | Axel Bex 03:20 Latest EV-103 update further supports enfortumab for untreated advanced UC | Jonathan Rosenberg 03:23 ATLANTIS rules out cabozantinib as a maintenance option for mUC | Robert Jones 04:35 Support for continuing enzalutamide after mCRPC progression | Axel Merseburger 05:02 Mapping the impact of COVID-19 on genitourinary cancers| Chris Labaki Similar videos 06:39 Expert highlights: Lung cancer research from ASCO 2018 | Lecia Sequist 07:31 Lecia V. Sequist, MD, MPH: Lung Cancer Genomics 01:22 GRACEcastUC-066_Lung_Dr. Lecia Sequist on Relevant Emerging Molecular Targets in Lung Cancer 02:12 Dr. Lecia Sequist talks about Early Detection with Billy Costa 02:05 ESMO Vision stories of Specialised Education: Nicolas Girard, ESMO Guidelines author 27:03 Dr. Lecia Sequist (Pt. 1): Combining Interests in Science and Practical Issues in Cancer Care 01:03 Dr. Sequist Discusses Combination Regimens in EGFR+ NSCLC 04:49 TATTON trial – Savolitinib plus osimertinib in EGFR-mutated, MET-amplified NSCLC | Lecia Sequist 2:10:48 The Lung Cancer Living Room™ - Best of ASCO - July 18th, 2017 - Full 2-Hour Episode 02:25 Dr. Sequist Discusses the OS Analysis of LUX-Lung 3 and LUX-Lung 6 11:29 GRACEcast-069_Lung-Cancer_Sequist on Results from Re-Biopsying Lesions 03:08 Recommended Mutation Testing in Lung Cancer 1:02:50 New Strategies in Lung Cancer: Innovations in Clinical Trials, Treatments, and Patient Care 2:58:06 OncoAlert Colloquium Day 2 (Lung Cancer & SIOG Session) 02:30 TATTON: Osimertinib plus savolitinib for patients with EGFR-mutant, MET-amplified NSCLC after pr... 23:57 Dr. Lecia Sequist (Pt. 2): Post-ASCO Debrief & Efforts with IASLC 01:20 Pooled Analysis Chemo+IO vs. IO in PDL1 High Cohort | Nagashree Seetharamu, MD | ASCO22 Lung Updates 06:31 Solange Peters & Rolf Stahel comment the European Lung Cancer Conference (ELCC) 2018 Highlights 03:14 Dr. Roy Herbst, Yale Cancer Center/Smilow Cancer Hospital More results